Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Winette T.A. van der Graaf, Anders Krarup‐Hansen et al.|The Lancet Oncology|2014Cited by 1.2k
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Beate Timmermann, Stefan Bielack et al.|European Journal of Cancer|2019Cited by 724
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upPancras C.W. Hogendoorn, D. Vanel, Nick Athanasou et al.|Annals of Oncology|2010Cited by 718
The expanding role of primary care in cancer controlGreg Rubin, Camilla Zimmermann, Annette J. Berendsen et al.|The Lancet Oncology|2015Cited by 544
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan Bielack, Mark L. Bernstein, Sigbjørn Smeland et al.|Journal of Clinical Oncology|2015Cited by 419